UroGen Pharma URGN reported its Q4 earnings results on Monday, March 21, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
UroGen Pharma missed estimated earnings by 8.55%, reporting an EPS of $-1.27 versus an estimate of $-1.17.
Revenue was up $8.21 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.06 which was followed by a 7.46% drop in the share price the next day.
Here's a look at UroGen Pharma's past performance:
Quarter | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
---|---|---|---|---|
EPS Estimate | -1.29 | -1.27 | -1.29 | -1.37 |
EPS Actual | -1.35 | -1.17 | -1.17 | -1.38 |
Revenue Estimate | 15.42M | 10.21M | 9.05M | 7.57M |
Revenue Actual | 11.35M | 13.03M | 7.49M | 7.97M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.